FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235 Estimated average burden hours per response... 3235-0287 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)													
Name and Address of Reporting Person * Beever Charles				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]						n	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
		(First) ARMACEUTICA R DRIVE	* * * * * * * * * * * * * * * * * * *	3. Date o			nsact	tion (Month/Da	ay/Year)			e title below)		r (specify below)
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
	ILLE, MD		(7:-)												
(Cit	iy)	(State)	(Zip)						ive Securities	Acquired	Disposed	of, or Bene	eficially Own	ed	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Yea		ate, if ((A)	or Disposed of Str. 3, 4 and 5) (A) or	of (D) Own Tran	5. Amount of Securities Benet Owned Following Reported Transaction(s) (Instr. 3 and 4)		ed (Ownership of Form:	Beneficial Ownership	
							Coo	de V Am	ount (D)	Price			(Instr. 4)	
Reminder:	Report on a	separate line for eac						Persons containe form disp	who respond in this forrolays a curre	n are not ently valid	required I OMB co	to respon	d unless th		174 (9-02)
								, ·	ed of, or Bene vertible securi	•	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction of Deriv (Instr. 8) Secun Acqu (A) o Dispo (D) (Instr. 8)		Derivati Securition Acquirent (A) or Dispose	Expiration (Month/I (7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form of Derivative Security: Direct (D or Indirect	(Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (right to buy)	\$ 1.20							05/01/2007	05/01/2016	Common Stock	20,000		20,000	D	
Stock Options (right to buy)	\$ 1.40							06/11/2008	06/11/2017	Common Stock	¹ 20,000		20,000	D	
Stock Options (right to buy)	\$ 3.24							(1)	06/30/2018	Common Stock	20,000		20,000	D	
Stock Options (right to buy)	\$ 1.28	06/01/2009		A		20,000		(2)	06/01/2019	Common Stock	¹ 20,000	\$ 0	20,000	D	

Reporting Owners

Bonostino Orano Norro / Addisor	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Beever Charles C/O REXAHN PHARMACEUTICALS, INC 9620 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850	Х					

Signatures

/s/ Tae Heum Jeong, as attorney-in-fact for Charles Beever	06/02/2009
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options vest and become exercisable in full on June 30, 2009.
- (2) These options vest and become exercisable in full on June 1, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.